Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasted to Post Q1 2024 Earnings of ($0.13) Per Share

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Lexicon Pharmaceuticals in a note issued to investors on Tuesday, April 30th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will earn ($0.13) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals’ Q2 2024 earnings at ($0.13) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at ($0.50) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.07 EPS.

LXRX has been the subject of a number of other reports. SVB Leerink began coverage on Lexicon Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $5.00 target price for the company. StockNews.com raised Lexicon Pharmaceuticals to a “sell” rating in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 23rd.

Lexicon Pharmaceuticals Trading Up 3.0 %

Shares of LXRX opened at $1.70 on Thursday. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.79. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07. The stock has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $1.74. The stock has a market cap of $418.60 million, a PE ratio of -2.13 and a beta of 1.38.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. boosted its position in Lexicon Pharmaceuticals by 22.0% in the 4th quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 5,813 shares during the last quarter. Swiss National Bank boosted its position in Lexicon Pharmaceuticals by 4.4% in the 3rd quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 10,300 shares during the last quarter. Cantor Fitzgerald L. P. bought a new position in Lexicon Pharmaceuticals in the 4th quarter valued at $25,000. Pinnacle Associates Ltd. boosted its position in Lexicon Pharmaceuticals by 1.0% in the 1st quarter. Pinnacle Associates Ltd. now owns 1,747,830 shares of the biopharmaceutical company’s stock valued at $4,195,000 after buying an additional 17,009 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Lexicon Pharmaceuticals by 65.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 46,930 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,601 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.